Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 16/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263231 | 1.00 | PDK1 (0.53) | PDK1HRH3DRD4DRD2 | |
| SCHEMBL23107088 | 0.86 | PDK1 (0.50) | PDK1HRH3DRD4DRD2 | |
| SCHEMBL24477209 | 0.84 | PDK1 (0.56) | PDK1HRH3DRD4 | |
| SCHEMBL5363661 | 0.84 | PDK1 (0.51) | PDK1HRH3DRD4DRD2 | |
| SCHEMBL5150493 | 0.81 | PDK1 (0.53) | PDK1HRH3DRD4DRD2 | |
| SCHEMBL295933 | 0.81 | PDK1 (0.53) | PDK1HRH3DRD4DRD2 | |
| SCHEMBL5368215 | 0.81 | PDK1 (0.49) | PDK1HRH3DRD4 | |
| SCHEMBL12337453 | 0.81 | HRH3 (0.51) | PDK1HRH3DRD4 | |
| SCHEMBL5148568 | 0.81 | PDK1 (0.49) | PDK1HRH3DRD4DRD2 | |
| SCHEMBL295932 | 0.81 | PDK1 (0.49) | PDK1HRH3DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | PDK1 185/4885HRH3 387/4885DRD4 4878/4885 |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | PDK1 925/4885HRH3 351/4885DRD4 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.